Pfizer Inc.

NYSE:PFE  
53.91
-0.08 (-0.15%)
5:11:20 PM EDT: $53.91 0.00 (0.00%)
Regulatory, Earnings Announcements

Pfizer Announces Positive Top-Line Results For Phase 3 Trial Of Etrasimod In Ulcerative Colitis Patients

Published: 03/23/2022 10:54 GMT
Pfizer Inc. (PFE) - Pfizer Announces Positive Top-line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients.
Pfizer Inc - Safety Profile Consistent With Previous Phase 2 Studies.
Pfizer Inc - Elevate 12 Study Met Primary and Key Secondary Endpoints of Improving Clinical Remission at Week 12.
Pfizer Inc - Etrasimod Patients Achieved Statistically Significant Improvements in Primary Endpoint of Clinical Remission at Week 12 Versus Placebo.
Pfizer Inc - Results From Elevate 52 Study Will Be Available by End of Q1.
Revenue is expected to be $26.02 Billion
Adjusted EPS is expected to be $1.81

Next Quarter Revenue Guidance is expected to be $25.94 Billion
Next Quarter EPS Guidance is expected to be $1.88

More details on our Analysts Page.